Vimarsana
Biggest News Aggregation in the World

Page 41 - Exact Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Exact Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Exact Sciences Today - Breaking & Trending Today

Fungi, yerba mate waste and cassava starch: Argentina's alternatives to plastic | Climate - Vimarsana News

Fungi, yerba mate waste and cassava starch: Argentina's alternatives to plastic | Climate

Scientists and entrepreneurs in the country are exploring ways to replace plastic packaging with everyday materials

Source: elpais.com
Pregnancy After Breast Cancer in Young BRCA Carriers - Vimarsana News

Pregnancy After Breast Cancer in Young BRCA Carriers

This retrospective cohort study assesses the cumulative incidence of pregnancy after cancer and disease-free survival in BRCA carriers diagnosed with invasive b

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings - Vimarsana News

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings

/PRNewswire/ -- Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.3 million to 23 organizations...

Digital diagnostics: A path forward for IVD - Vimarsana News

Digital diagnostics: A path forward for IVD

In vitro diagnostics players are being tested as their offerings are increasingly commoditized. Digital diagnostics offers a path to growth.

Neoadjuvant chemotherapy can eliminate need for regional nodal irradiation in breast cancer - Vimarsana News

Neoadjuvant chemotherapy can eliminate need for regional nodal irradiation in breast cancer

For patients whose breast cancer converted from lymph node-positive to lymph node-negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation (RNI) did not increase the risk of disease recurrence or death five years after surgery, according to results from the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.